Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

@article{Bone1997DoseresponseRF,
  title={Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.},
  author={H G Bone and Robert W. Downs and Joseph R. Tucci and Steven T. Harris and Robert S. Weinstein and Angelo A. Licata and Michael R Mcclung and Donald B. Kimmel and Barry J. Gertz and Ellen Hale and William J Polvino},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1997},
  volume={82 1},
  pages={265-74}
}
Alendronate (ALN) is an aminobisphosphonate employed as an antiresorptive agent in the treatment of osteoporosis. The present study was carried out to determine dose-response relationships, particularly the effects of relatively low doses of ALN, on bone mineral density (BMD), biochemical indexes of bone and mineral metabolism, and bone histology, with particular attention to effects in elderly women. This prospective, randomized, double blind, 2-yr multicenter study compared the effects of… CONTINUE READING